BeiGene Ltd
(SHSE:688235)
Â¥
123
0.99 (0.81%)
Market Cap: 120.88 Bil
Enterprise Value: 108.32 Bil
PE Ratio: 0
PB Ratio: 4.85
GF Score: 55/100 - Beigene Ltd at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Beigene Ltd Investors and Analysts Panel Event Presentation TranscriptDec 11, 2023
- Beigene Ltd at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Beigene Ltd Investor Research and Development Day TranscriptJul 18, 2023
- Beigene Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2023
- Beigene Ltd at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Beigene Ltd to Discuss Final Results of the ALPINE Trial Late-Breaker Presentation TranscriptDec 13, 2022
- Beigene Ltd to Discuss Final Results of the ALPINE Trial Q&A Call TranscriptDec 12, 2022
- Beigene Ltd at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Beigene Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Beigene Ltd at Cowen Health Care Conference (Virtual) TranscriptMar 07, 2022
- Beigene Ltd at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 10, 2022
- Beigene Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- Beigene Ltd R&D Day TranscriptAug 25, 2021
- Beigene Ltd to Discuss Interim Analysis of the ALPINE Trial and Data Presented at EHA2021 Call TranscriptJun 11, 2021
- Beigene Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Beigene Ltd China National Reimbursement Drug List (NRDL) Results Conference Call TranscriptDec 29, 2020
- Beigene Ltd at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Beigene Ltd to Discuss the Company's Early Development Pipeline and Research Call TranscriptJul 09, 2020
- Beigene Ltd at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- Beigene Ltd at American Society of Clinical Oncology (ASCO) Virtual Scientific Program Call TranscriptMay 30, 2020
- Beigene Ltd at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Beigene Ltd Update Call: ASPEN Trial Readout TranscriptDec 16, 2019
- Beigene Ltd Corporate Update: Global Strategic Oncology Collaboration with Amgen TranscriptNov 01, 2019
- Beigene Ltd at Morgan Stanley Healthcare Conference TranscriptSep 10, 2019
- Beigene Ltd Update Call TranscriptSep 08, 2019
- Beigene Ltd Conference Call to Discuss Clinical Data on Zanubrutinib at 15th International Conference on Malignant Lymphoma (ICML) TranscriptJun 20, 2019
- Beigene Ltd at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2019
- Beigene Ltd at Barclays Global Healthcare Conference TranscriptMar 13, 2019
- Q4 2018 Beigene Ltd Earnings Call TranscriptFeb 27, 2019Earnings
Beigene Ltd at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023 / 01:20PM GMT
Release Date Price:
Â¥135.36
(+7.06%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Okay. Thank you, everyone. Appreciate that. With that, happy to have with me Mr. Mehrdad Mobasher, CMO of Hematology from BeiGene; and Mark Lanasa, CMO of Solid Tumors for BeiGene. Thank you both for joining us.
Mehrdad Mobasher
BeiGene, Ltd. - Chief Medical Officer of Hematology
Appreciate it.
Mark Lanasa
BeiGene, Ltd. - Senior VP & Chief Medical Officer for Solid Tumors
Appreciate it.
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Before we get into any pipeline-related and Brukinsa-related Q&A, I thought it might be good just to level set for the audience, if you could both just provide a quick overview of what you think some of the key inflection points have been across your respective areas of work at BeiGene for this year?
Mehrdad Mobasher
BeiGene, Ltd. - Chief Medical Officer of Hematology
So maybe I'll start first with
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)